Smoking cessation treatment and outcomes patterns simulation: A new framework for evaluating the potential health and economic impact of smoking cessation interventions

PharmacoEconomics

Volumn 31, Issue 9, 2013, Pages 767-780

  Getsios, Denis ^a   Marton, Jeno P ^b   Revankar, Nikhil ^a   Ward, Alexandra J ^a   Willke, Richard J ^b   Rublee, Dale ^b   Ishak, K Jack ^a   Xenakis, James G ^a  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; VARENICLINE;

ABSTINENCE; ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; ECONOMIC ASPECT; FEMALE; HEALTH CARE COST; HEART INFARCTION; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MORTALITY; NICOTINE REPLACEMENT THERAPY; PATIENT COUNSELING; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; RELAPSE; SIMULATION; SMOKING CESSATION; TOBACCO DEPENDENCE;

ADULT; BENZAZEPINES; BUPROPION; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; MODELS, ECONOMIC; QUALITY OF LIFE; QUINOXALINES; RECURRENCE; SMOKING CESSATION; TOBACCO USE DISORDER; TREATMENT OUTCOME;

EID: 84883498250     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0070-5     Document Type: Article

References (59)

1. Centers for Disease Control and Prevention (CDC). Annual smoking-attributable mortality, years of potential life lost, and economic costs - United States, 1995-1999. MMWR Morb Mortal Wkly Rep. 2002;14:300-3.
2. Centers for Disease Control and Prevention (CDC). State-specific smoking-attributable mortality and years of potential life lost - United States, 2000-2004. MMWR Morb Mortal Wkly Rep. 2009;58(2):29-33.
3. Agaku I, King B, Dube SR. Current cigarette smoking among adults - United States, 2011. MMWR Morb Mortal Wkly Rep. 2012;61(44):889-94.
4. Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction. 2004;99(1):29-38. (Pubitemid 38142221)
5. Hyland A, Borland R, Li Q, et al. Individual-level predictors of cessation behaviours among participants in the International Tobacco Control (ITC) Four Country Survey. Tob Control. 2006;15 Suppl. 3:iii83-94.
6. Hymowitz N, Cummings KM, Hyland A, et al. Predictors of smoking cessation in a cohort of adult smokers followed for five years. Tob Control. 1997;6(Suppl. 2):S57-62.
7. Fiore M, Jaen C, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Rockville: US Department of Health and Human Services, US Public Health Service; 2008
8. Fix BV, Hyland A, Rivard C, et al. Usage patterns of stop smoking medications in Australia, Canada, the United Kingdom, and the United States: findings from the 2006-2008 International Tobacco Control (ITC) Four Country Survey. Int J Environ Res Public Health. 2011;8(1):222-33.
9. Chantix U.S. Consumer Attitudes, Trends, and Usage Research - Wave 8 Report - April 2010; conducted by Opinion Research Corporation Guideline, Inc., Princeton NJ and Pfizer, Inc. New York (data on file)
10. Yeomans K, Payne KA, Marton JP, et al. Smoking, smoking cessation and smoking relapse patterns: a web-based survey of current and former smokers in the US. Int J Clin Pract. 2011;65(10):1043-54.
11. Ferguson J, Bauld L, Chesterman J, et al. The English smoking treatment services: one-year outcomes. Addiction. 2005;100(Suppl. 2):59-69. (Pubitemid 40525071)
12. Fiore M, Jaén C, Baker T, et al. Treating tobacco use and dependence: 2008 update. Quick reference guide for clinicians. Rockville: US Department of Health and Human Services, US Public Health Service; 2009
13. Bolin K. Economic evaluation of smoking-cessation therapies: a critical and systematic review of simulation models. Pharmacoeconomics. 2012;30(7):551-64.
14. Olsen KR, Bilde L, Juhl HH, et al. Cost-effectiveness of the Danish smoking cessation interventions: subgroup analysis based on the Danish Smoking Cessation Database. Eur J Health Econ. 2006;7(4):255-64.
15. Levy DT, Friend K. A simulation model of policies directed at treating tobacco use and dependence. Med Decis Making. 2002;22(1):6-17. (Pubitemid 34087686)
16. Xenakis JG, Kinter ET, Ishak KJ, et al. A discrete-event simulation of smoking-cessation strategies based on varenicline pivotal trial data. Pharmacoeconomics. 2011;29(6):497-510.
17. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):47-55.
18. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):56-63.
19. Aubin HJ, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax. 2008;63(8):717-24.
20. Rigotti NA, Pipe AL, Benowitz NL, et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation. 2010;121(2):221-9.
21. Tashkin DP, Rennard S, Hays JT, et al. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest. 2011;139(3):591-9.
22. Thun MJ. Data from Cancer Prevention Study II, 1982-1988 [provided by author - Michael J. Thun]
23. Shibuya K, Mathers C, Lopez A. Chronic obstructive pulmonary disease (COPD): consistent estimates of incidence, prevalence, and mortality by WHO region [DRAFT] [online]; 2001. http://www.who.int/healthinfo/statistics/bod- copd.pdf (Accessed 8 Mar 2010)
24. Centers for Disease Control and Prevention (CDC). Prevalence of heart disease - United States 2005 [online]; 2007. http://www.cdc.gov/mmwr/preview/ mmwrhtml/mm5606a2.htm#fig (Accessed 8 Mar 2010)
25. Bureau of Labor Statistics (BLS). United States Bureau of Labor Statistics website [online]; 2010. http://www.bls.gov (Accessed May 2010)
26. Lloyd-Jones D. Prevalence of stroke by age and sex (NHANES: 2003-2006) [online]; 2010. http://circ.ahajournals.org/cgi/content/full/121/7/e46/ FIG36192671 (Accessed 8 Mar 2010)
27. Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev. 2005;(2):CD001292
28. Wetter DW, Kenford SL, Welsch SK, et al. Prevalence and predictors of transitions in smoking behavior among college students. Health Psychol. 2004;23(2):168-77. (Pubitemid 38365276)
29. Hoogenveen RT, van Baal PH, Boshuizen HC, et al. Dynamic effects of smoking cessation on disease incidence, mortality and quality of life: the role of time since cessation. Cost Eff Resour Alloc. 2008;6:1. (Pubitemid 351418914)
30. SEER. SEER Cancer Statistics Review 1975-2006. Cancer of the lung and bronchus (invasive) Table 15.9. SEER incidence and U.S. death rates, age-adjusted and age-specific rates, by race and sex, years 2002-2006 [online]; 2006. http://seer.cancer.gov/csr/1975-2006/results-single/sect-15-table.09.pdf (Accessed 8 Mar 2010)
31. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46-215.
32. Williams GR, Jiang JG, Matchar DB, et al. Incidence and occurrence of total (first-ever and recurrent) stroke. Stroke. 1999;30(12):2523-8.
33. SEER. SEER Cancer Statistics Review 1975-2006. U.S. complete prevalence counts, invasive cancers only, January 1, 2006 by age at prevalence. Table 1.22 [online]; 2006. http://seer.cancer.gov/csr/1975-2006/results-single/sect-01- table.22-2pgs.pdf (Accessed 8 Mar 2010)
34. University of California Berkeley (USA), Max Planck Institute for Demographic Research (Germany). Human Mortality Database [online]; 2010. http://www.mortality.org or http://www.humanmortality.de (Accessed 8 Mar 2010)
35. Bronnum-Hansen H, Jorgensen T, Davidsen M, et al. Survival and cause of death after myocardial infarction: the Danish MONICA study. J Clin Epidemiol. 2001;54(12):1244-50. (Pubitemid 34002977)
36. de Torres JP, Cote CG, Lopez MV, et al. Sex differences in mortality in patients with COPD. Eur Respir J. 2009;33(3):528-35.
37. Tammemagi CM, Neslund-Dudas C, Simoff M, et al. Smoking and lung cancer survival: the role of comorbidity and treatment. Chest. 2004;125(1):27-37. (Pubitemid 38114560)
38. Wolfe CD, Smeeton NC, Coshall C, et al. Survival differences after stroke in a multiethnic population: follow-up study with the South London stroke register. BMJ. 2005;331(7514):431. (Pubitemid 41176379)
39. Sullivan PW, Ghushchyan V. Mapping the EQ-5D index from the SF-12: US general population preferences in a nationally representative sample. Med Decis Making. 2006;26(4):401-9. (Pubitemid 44050844)
40. Howard P, Knight C, Boler A, et al. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers. Pharmacoeconomics. 2008;26(6):497-511. (Pubitemid 351704858)
41. Mannino DM, Buist AS, Petty TL, et al. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax. 2003;58(5):388-93. (Pubitemid 36560940)
42. Spencer M, Briggs AH, Grossman RF, et al. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics. 2005;23(6):619-37. (Pubitemid 40994129)
43. Trippoli S, Vaiani M, Lucioni C, et al. Quality of life and utility in patients with non-small cell lung cancer. Quality-of-life Study Group of the Master 2 Project in Pharmacoeconomics. Pharmacoeconomics. 2001;19(8):855-63.
44. Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993;13(2):89-102. (Pubitemid 23113445)
45. Hay JW, Sterling KL. Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease. Pharmacoeconomics. 2005;23(2):133-41. (Pubitemid 40460653)
46. Duncan PW, Lai SM, Keighley J. Defining post-stroke recovery: implications for design and interpretation of drug trials. Neuropharmacology. 2000;39(5):835-41. (Pubitemid 30103686)
47. Tengs TO, Lin TH. A meta-analysis of quality-of-life estimates for stroke. Pharmacoeconomics. 2003;21(3):191-200. (Pubitemid 36286663)
48. Bureau of Labor Statistics (BLS). United States Bureau of Labor Statistics: Consumer Price Index website [online]; 2012. http://www.bls.gov/cpi/ home.htm (Accessed Jun 2012)
49. O'Sullivan AK, Rubin J, Nyambose J, et al. Cost estimation of cardiovascular disease events in the US. Pharmacoeconomics. 2011;29(8):693-704.
50. Dalal AA, Christensen L, Liu F, et al. Direct costs of chronic obstructive pulmonary disease among managed care patients. Int J Chron Obstruct Pulmon Dis. 2010;5:341-9.
51. Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011;103(2):117-28.
52. MAG Mutual Healthcare Solutions. Physicians' Fee and Coding Guide: 2012. MAG Mutual Healthcare Solutions Incorporated; 2012.
53. Red Book Online. New York: Thomson-Reuters; 2012. http://www.redbook.com/ redbook/online/ (Accessed 8 Jun 2012)
54. Nicoderm CQ website [online]; 2012. http://www.nicodermcq.com/Quit-Place- Dose.aspx (Accessed 8 Jun 2012)
55. Nicorette. Frequently asked questions [online]; 2012. http://www.nicorette.com/Faqs.aspx#lnk16 (Accessed 1 Jun 2012)
56. Nicotrol® NS (nicotine nasal spray) prescribing information [online]; 2012. http://media.pfizer.com/files/products/uspi-nicotrol.pdf (Accessed 5 Jun 2012)
57. Nicorette® Lozenge website [online]; 2012. http://www.commitlozenge. com/Quit-Place-Dose.aspx (Accessed 5 Jun 2012)
58. Department of Health and Human Services: Centers for Medicare and Medicaid Services. Tobacco-Use Cessation Counseling Services. Baltimore: Centers for Medicare and Medicaid Services; 2012. https://www.cms.gov/Outreach-and- Education/Medicare-Learning-Network-MLN/MLNProducts/downloads/smoking.pdf (Accessed Feb 2012)
59. Office on Smoking and Health (US). Women and smoking: a report of the surgeon general. Atlanta: Centers for Disease Control and Prevention (US); 2001. http://www.ncbi.nlm.nih.gov/books/NBK44303/ [Accessed Jun 2013]